



## Annex to IPER

### CLAIMS

- Sub  
a2
1. Use of an antibody which is directed against the cellular membrane antigen Ep-CAM for the preparation of a pharmaceutical composition for the prophylactic and/or therapeutic vaccination against cancer.
  2. The use of claim 1, wherein the antibody is of animal origin.
  3. The use of claim 1 or 2, wherein the antibody is a monoclonal antibody.
  4. The use of claim 3, wherein the antibody is a murine monoclonal antibody, wherein the variable region of the heavy chain is the amino acid sequence as shown in SEQ ID NO:1 and wherein the variable region of the light chain is the amino acid sequence as shown in SEQ ID NO:2.
  5. The use of any one of claims 1 to 3, wherein the antibody has the same fine specificity of binding as the antibody as defined in claim 4.
  6. The use of any one of claims 1 to 5, wherein two or more antibodies which are directed against different epitopes of the membrane antigen are used in combination with each other.
  7. The use of any one of claims 1 to 6, wherein the pharmaceutical composition further comprises also at least one vaccine adjuvant.
  8. The use of any one of claims 1 to 7, wherein the pharmaceutical composition is suitable for the administration of the antibody at a dosage in the range of 0.01 to 4 mg antibody.
  9. The use of any one of claims 1 to 9, wherein the pharmaceutical composition is suitable for the administration by subcutaneous, intradermal or intramuscular injection.
- 09889300-091301
- Ad B7